Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Edwards Lifesciences CorpEW · Entity 3026 | CVP, EMEACLA and JAPAC | July 07, 2024 | July 08, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Edwards Lifesciences Corp
Report date July 07, 2024 · Filed July 08, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 184,685.8054 |
Reported balance
After 2024-07-07 transaction · row 1
1 source rowRow 1 · 2024-07-07 · Tax withholding · Disposed 82 · Balance 184,685.8054 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 07, 2020 Filed May 8, 2020 23:33 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantCommon Stock | 1,150 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-007342 · doc4.xml · nonDerivative · entry 1 Lemercier Jean-Luc M · CIK 0001710625 · CVP, EMEA, Canada, Latin Amer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,081.0477 F1 · shares: These restricted stock units were granted on May 7, 2020 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. Read SEC document |
| April 27, 2020 Filed Apr 27, 2020 22:05 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 3,470 | $0.00 Strike: $35.79 | $0.00 |
DisclosureSEC source: 0001225208-20-006773 · doc4.xml · derivative · entry 3 Lemercier Jean-Luc M · CIK 0001710625 · CVP, EMEA, Canada, Latin Amer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,470 shares Expires 2020-05-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 24, 2019. Read SEC document |
| April 27, 2020 Filed Apr 27, 2020 22:05 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 3,470 | $223.50 | $775,545.00 |
DisclosureSEC source: 0001225208-20-006773 · doc4.xml · nonDerivative · entry 2 Lemercier Jean-Luc M · CIK 0001710625 · CVP, EMEA, Canada, Latin Amer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,931.0477 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 24, 2019. Read SEC document |
| April 27, 2020 Filed Apr 27, 2020 22:05 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 3,470 | $35.79 | $124,173.95 |
DisclosureSEC source: 0001225208-20-006773 · doc4.xml · nonDerivative · entry 1 Lemercier Jean-Luc M · CIK 0001710625 · CVP, EMEA, Canada, Latin Amer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,401.0477 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 24, 2019. Read SEC document |
| April 01, 2020 Filed Apr 1, 2020 22:30 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 3,470 | $0.00 Strike: $35.79 | $0.00 |
DisclosureSEC source: 0001225208-20-005797 · doc4.xml · derivative · entry 3 Lemercier Jean-Luc M · CIK 0001710625 · CVP, EMEA, Canada, Latin Amer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,470 Underlying: Common Stock · 3,470 shares Expires 2020-05-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 24, 2019. Read SEC document |
| April 01, 2020 Filed Apr 1, 2020 22:30 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 3,470 | $180.84 | $627,514.80 |
DisclosureSEC source: 0001225208-20-005797 · doc4.xml · nonDerivative · entry 2 Lemercier Jean-Luc M · CIK 0001710625 · CVP, EMEA, Canada, Latin Amer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,931.0477 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 24, 2019. Read SEC document |
| April 01, 2020 Filed Apr 1, 2020 22:30 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 3,470 | $35.79 | $124,173.95 |
DisclosureSEC source: 0001225208-20-005797 · doc4.xml · nonDerivative · entry 1 Lemercier Jean-Luc M · CIK 0001710625 · CVP, EMEA, Canada, Latin Amer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,401.0477 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 24, 2019. Read SEC document |
| February 27, 2020 Filed Feb 28, 2020 00:11 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 3,470 | $0.00 Strike: $35.79 | $0.00 |
DisclosureSEC source: 0001225208-20-003736 · doc4.xml · derivative · entry 3 Lemercier Jean-Luc M · CIK 0001710625 · CVP, EMEA, Canada, Latin Amer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,940 Underlying: Common Stock · 3,470 shares Expires 2020-05-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 24, 2019. Read SEC document |
| February 27, 2020 Filed Feb 28, 2020 00:11 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 3,470 | $217.53 | $754,829.10 |
DisclosureSEC source: 0001225208-20-003736 · doc4.xml · nonDerivative · entry 2 Lemercier Jean-Luc M · CIK 0001710625 · CVP, EMEA, Canada, Latin Amer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,817.5844 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 24, 2019. Read SEC document |
| February 27, 2020 Filed Feb 28, 2020 00:11 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 3,470 | $35.79 | $124,173.95 |
DisclosureSEC source: 0001225208-20-003736 · doc4.xml · nonDerivative · entry 1 Lemercier Jean-Luc M · CIK 0001710625 · CVP, EMEA, Canada, Latin Amer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,287.5844 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 24, 2019. Read SEC document |
| February 03, 2020 Filed Feb 4, 2020 01:56 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 3,470 | $0.00 Strike: $35.79 | $0.00 |
DisclosureSEC source: 0001225208-20-001529 · doc4.xml · derivative · entry 3 Lemercier Jean-Luc M · CIK 0001710625 · CVP, EMEA, Canada, Latin Amer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,410 Underlying: Common Stock · 3,470 shares Expires 2020-05-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 24, 2019. Read SEC document |
| February 03, 2020 Filed Feb 4, 2020 01:56 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 3,470 | $219.50 | $761,665.00 |
DisclosureSEC source: 0001225208-20-001529 · doc4.xml · nonDerivative · entry 2 Lemercier Jean-Luc M · CIK 0001710625 · CVP, EMEA, Canada, Latin Amer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,817.5844 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 24, 2019. Read SEC document |
| February 03, 2020 Filed Feb 4, 2020 01:56 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 3,470 | $35.79 | $124,173.95 |
DisclosureSEC source: 0001225208-20-001529 · doc4.xml · nonDerivative · entry 1 Lemercier Jean-Luc M · CIK 0001710625 · CVP, EMEA, Canada, Latin Amer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,287.5844 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 24, 2019. Read SEC document |
| May 14, 2019 Filed May 14, 2019 23:00 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Tax withholdingCommon Stock | 36 | $178.17 | $6,414.12 |
DisclosureSEC source: 0001225208-19-007994 · doc4.xml · nonDerivative · entry 2 Lemercier Jean-Luc M · CIK 0001710625 · CVP, EMEA, Canada, Latin Amer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,651.8535 Read SEC document |
| May 12, 2019 Filed May 14, 2019 23:00 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Tax withholdingCommon Stock | 22 | $181.10 | $3,984.20 |
DisclosureSEC source: 0001225208-19-007994 · doc4.xml · nonDerivative · entry 1 Lemercier Jean-Luc M · CIK 0001710625 · CVP, EMEA, Canada, Latin Amer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,687.8535 Read SEC document |
| May 08, 2019 Filed May 10, 2019 21:00 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantPerformance Rights · Derivative | 1,625 | $0.00 | $0.00 |
DisclosureSEC source: 0001223203-19-000031 · primary_doc.xml · derivative · entry 3 Lemercier Jean-Luc M · CIK 0001710625 · CVP, EMEA, Canada, Latin Amer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,625 Underlying: Common Stock · 1,625 shares Expires 2026-05-07 F3 · derivative.exercise_price: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 8, 2019 and scheduled to vest on May 8, 2022. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. F3 · shares: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 8, 2019 and scheduled to vest on May 8, 2022. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. F3 · derivative.exercise_date: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 8, 2019 and scheduled to vest on May 8, 2022. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. F3 · derivative.expiration_date: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 8, 2019 and scheduled to vest on May 8, 2022. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. F3 · derivative.underlying_shares: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 8, 2019 and scheduled to vest on May 8, 2022. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. Read SEC document |
| May 08, 2019 Filed May 10, 2019 21:00 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantEmployee Stock Option (Right to Acquire) · Derivative | 12,800 | $0.00 Strike: $177.77 | $0.00 |
DisclosureSEC source: 0001223203-19-000031 · primary_doc.xml · derivative · entry 2 Lemercier Jean-Luc M · CIK 0001710625 · CVP, EMEA, Canada, Latin Amer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,800 Underlying: Common Stock · 12,800 shares Expires 2026-05-07 F2 · derivative.exercise_date: These options were granted on May 8, 2019 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one month after the grant date in 36 approximately equal annual installments. Read SEC document |
| May 08, 2019 Filed May 10, 2019 21:00 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantCommon Stock | 1,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001223203-19-000031 · primary_doc.xml · nonDerivative · entry 1 Lemercier Jean-Luc M · CIK 0001710625 · CVP, EMEA, Canada, Latin Amer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,709.8535 F1 · shares: These restricted stock units were granted on May 8, 2019 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become 50% vested three years after the grant date and 50% vested four years after the grant date. Read SEC document |
| May 06, 2019 Filed May 7, 2019 21:25 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 4,188 | $0.00 Strike: $42.73 | $0.00 |
DisclosureSEC source: 0001510192-19-000051 · primary_doc.xml · derivative · entry 3 Lemercier Jean-Luc M · CIK 0001710625 · CVP, EMEA, Canada, Latin Ameri 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,188 shares Expires 2019-05-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 21, 2019. Read SEC document |
| May 06, 2019 Filed May 7, 2019 21:25 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 4,188 | $176.17 | $737,799.96 |
DisclosureSEC source: 0001510192-19-000051 · primary_doc.xml · nonDerivative · entry 2 Lemercier Jean-Luc M · CIK 0001710625 · CVP, EMEA, Canada, Latin Ameri 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,409.8535 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 21, 2019. Read SEC document |
| May 06, 2019 Filed May 7, 2019 21:25 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 4,188 | $42.73 | $178,932.30 |
DisclosureSEC source: 0001510192-19-000051 · primary_doc.xml · nonDerivative · entry 1 Lemercier Jean-Luc M · CIK 0001710625 · CVP, EMEA, Canada, Latin Ameri 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,597.8535 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 21, 2019. Read SEC document |
| April 09, 2019 Filed Apr 9, 2019 19:09 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 4,186 | $0.00 Strike: $42.73 | $0.00 |
DisclosureSEC source: 0001225208-19-006591 · doc4.xml · derivative · entry 3 Lemercier Jean-Luc M · CIK 0001710625 · CVP, EMEA, Canada, Latin Amer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,188 Underlying: Common Stock · 4,186 shares Expires 2019-05-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 21, 2019. Read SEC document |
| April 09, 2019 Filed Apr 9, 2019 19:09 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 4,186 | $188.23 | $787,930.78 |
DisclosureSEC source: 0001225208-19-006591 · doc4.xml · nonDerivative · entry 2 Lemercier Jean-Luc M · CIK 0001710625 · CVP, EMEA, Canada, Latin Amer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,409.8535 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 21, 2019. Read SEC document |
| April 09, 2019 Filed Apr 9, 2019 19:09 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 4,186 | $42.73 | $178,846.85 |
DisclosureSEC source: 0001225208-19-006591 · doc4.xml · nonDerivative · entry 1 Lemercier Jean-Luc M · CIK 0001710625 · CVP, EMEA, Canada, Latin Amer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,595.8535 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 21, 2019. Read SEC document |
| March 25, 2019 Filed Mar 25, 2019 23:44 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 4,186 | $0.00 Strike: $42.73 | $0.00 |
DisclosureSEC source: 0001225208-19-005776 · doc4.xml · derivative · entry 3 Lemercier Jean-Luc M · CIK 0001710625 · CVP, EMEA, Canada, Latin Amer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,374 Underlying: Common Stock · 4,186 shares Expires 2019-05-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 21, 2019. Read SEC document |
| March 25, 2019 Filed Mar 25, 2019 23:44 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 4,186 | $188.60 | $789,479.60 |
DisclosureSEC source: 0001225208-19-005776 · doc4.xml · nonDerivative · entry 2 Lemercier Jean-Luc M · CIK 0001710625 · CVP, EMEA, Canada, Latin Amer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,409.8535 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 21, 2019. Read SEC document |
| March 25, 2019 Filed Mar 25, 2019 23:44 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 4,186 | $42.73 | $178,846.85 |
DisclosureSEC source: 0001225208-19-005776 · doc4.xml · nonDerivative · entry 1 Lemercier Jean-Luc M · CIK 0001710625 · CVP, EMEA, Canada, Latin Amer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,595.8535 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 21, 2019. Read SEC document |
| May 17, 2018 Filed May 22, 2018 00:46 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantPerformance Rights · Derivative | 2,025 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-009681 · doc4.xml · derivative · entry 3 Lemercier Jean-Luc M · CIK 0001710625 · CVP, EMEA, Canada, Latin Amer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,025 Underlying: Common Stock · 2,025 shares Expires 2025-05-16 F3 · derivative.exercise_price: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 17, 2018 and scheduled to vest on May 17, 2021. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Award. F3 · shares: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 17, 2018 and scheduled to vest on May 17, 2021. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Award. F3 · derivative.exercise_date: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 17, 2018 and scheduled to vest on May 17, 2021. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Award. F3 · derivative.expiration_date: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 17, 2018 and scheduled to vest on May 17, 2021. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Award. F3 · derivative.underlying_shares: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 17, 2018 and scheduled to vest on May 17, 2021. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Award. Read SEC document |
| May 17, 2018 Filed May 22, 2018 00:46 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantEmployee Stock Option (Right to Acquire) · Derivative | 15,900 | $0.00 Strike: $135.83 | $0.00 |
DisclosureSEC source: 0001225208-18-009681 · doc4.xml · derivative · entry 2 Lemercier Jean-Luc M · CIK 0001710625 · CVP, EMEA, Canada, Latin Amer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,900 Underlying: Common Stock · 15,900 shares Expires 2025-05-16 F2 · derivative.exercise_date: These options were granted on May 17, 2018 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one month after the grant date in 36 approximately equal annual installments. Read SEC document |
| May 17, 2018 Filed May 22, 2018 00:46 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantCommon Stock | 1,625 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-009681 · doc4.xml · nonDerivative · entry 1 Lemercier Jean-Luc M · CIK 0001710625 · CVP, EMEA, Canada, Latin Amer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,373.0233 F1 · shares: These restricted stock units were granted on May 17, 2018 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become 50% vested three years after the grant date and 50% vested four years after the grant date. Read SEC document |
| May 14, 2018 Filed May 17, 2018 00:56 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Tax withholdingCommon Stock | 36 | $138.11 | $4,971.96 |
DisclosureSEC source: 0001225208-18-009500 · doc4.xml · nonDerivative · entry 1 Lemercier Jean-Luc M · CIK 0001710625 · CVP, EMEA, Canada, Latin Amer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,748.0233 Read SEC document |
| May 09, 2018 Filed May 10, 2018 22:50 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 5,634 | $0.00 Strike: $44.62 | $0.00 |
DisclosureSEC source: 0001225208-18-009119 · doc4.xml · derivative · entry 4 Lemercier Jean-Luc M · CIK 0001710625 · CVP, EMEA, Canada, Latin Amer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,634 shares Expires 2018-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 5, 2018. Read SEC document |
| May 09, 2018 Filed May 10, 2018 22:50 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 5,634 | $134.91 | $760,082.94 |
DisclosureSEC source: 0001225208-18-009119 · doc4.xml · nonDerivative · entry 3 Lemercier Jean-Luc M · CIK 0001710625 · CVP, EMEA, Canada, Latin Amer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,784.0233 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 5, 2018. Read SEC document |
| May 09, 2018 Filed May 10, 2018 22:50 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 5,634 | $44.62 | $251,360.91 |
DisclosureSEC source: 0001225208-18-009119 · doc4.xml · nonDerivative · entry 2 Lemercier Jean-Luc M · CIK 0001710625 · CVP, EMEA, Canada, Latin Amer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,418.0233 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 5, 2018. Read SEC document |
| May 08, 2018 Filed May 10, 2018 22:50 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Tax withholdingCommon Stock | 56 | $136.09 | $7,621.04 |
DisclosureSEC source: 0001225208-18-009119 · doc4.xml · nonDerivative · entry 1 Lemercier Jean-Luc M · CIK 0001710625 · CVP, EMEA, Canada, Latin Amer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,784.0233 Read SEC document |
| April 11, 2018 Filed Apr 12, 2018 23:55 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 5,633 | $0.00 Strike: $44.62 | $0.00 |
DisclosureSEC source: 0001225208-18-007725 · doc4.xml · derivative · entry 3 Lemercier Jean-Luc M · CIK 0001710625 · CVP, EMEA, Canada, Latin Amer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,634 Underlying: Common Stock · 5,633 shares Expires 2018-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 5, 2018. Read SEC document |
| April 11, 2018 Filed Apr 12, 2018 23:55 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 5,633 | $139.42 | $785,352.86 |
DisclosureSEC source: 0001225208-18-007725 · doc4.xml · nonDerivative · entry 2 Lemercier Jean-Luc M · CIK 0001710625 · CVP, EMEA, Canada, Latin Amer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,840.0233 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 5, 2018. Read SEC document |
| April 11, 2018 Filed Apr 12, 2018 23:55 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 5,633 | $44.62 | $251,316.30 |
DisclosureSEC source: 0001225208-18-007725 · doc4.xml · nonDerivative · entry 1 Lemercier Jean-Luc M · CIK 0001710625 · CVP, EMEA, Canada, Latin Amer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,473.0233 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 5, 2018. F2 · balance_after: This amount includes quarterly acquisition of shares under the Edwards Lifesciences Corporation Employee Stock Purchase Plan as reflected on the most recent report of the plan administrator Read SEC document |
| March 07, 2018 Filed Mar 9, 2018 00:35 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 5,633 | $0.00 Strike: $44.62 | $0.00 |
DisclosureSEC source: 0001225208-18-005784 · doc4.xml · derivative · entry 3 Lemercier Jean-Luc M · CIK 0001710625 · CVP, EMEA, Canada, Latin Amer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,267 Underlying: Common Stock · 5,633 shares Expires 2018-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 5, 2018. Read SEC document |
| March 07, 2018 Filed Mar 9, 2018 00:35 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 5,633 | $136.29 | $767,721.57 |
DisclosureSEC source: 0001225208-18-005784 · doc4.xml · nonDerivative · entry 2 Lemercier Jean-Luc M · CIK 0001710625 · CVP, EMEA, Canada, Latin Amer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,665.4191 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 5, 2018. Read SEC document |
| March 07, 2018 Filed Mar 9, 2018 00:35 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 5,633 | $44.62 | $251,316.30 |
DisclosureSEC source: 0001225208-18-005784 · doc4.xml · nonDerivative · entry 1 Lemercier Jean-Luc M · CIK 0001710625 · CVP, EMEA, Canada, Latin Amer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,298.4191 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 5, 2018. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.